Form 4: Ionis Pharmaceuticals Director Equity Grants Detailed

Joseph Loscalzo, a Director at Ionis Pharmaceuticals, received stock options and restricted stock units on July 1, 2026, with specific vesting and exercise terms.

Summary

• Joseph Loscalzo, a Director at Ionis Pharmaceuticals Inc. (IONS), was granted stock options and restricted stock units (RSUs) on July 1, 2026.
• The stock options have an exercise price of $79.19 and are for 5,369 shares, with vesting and exercisability beginning on July 1, 2027, and expiring on June 30, 2036.
• The RSUs are for 2,301 shares, with vesting occurring on the first anniversary of the grant date or the next annual stockholder meeting, whichever is earlier.
• These grants were adjusted to ensure the director's total annual equity compensation in 2026 does not exceed $400,000 based on grant date fair value.
• The RSUs will be delivered on July 15th following the vesting date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine equity grants to a director rather than significant financial performance or strategic shifts.

Positives

• Director Joseph Loscalzo received equity awards, aligning his interests with shareholders.
• The equity grants are structured with vesting periods, encouraging long-term commitment.
• The compensation policy ensures annual equity compensation for non-employee directors does not exceed $400,000, promoting fiscal prudence.

Negatives

• The earliest transaction date listed is July 1, 2026, which is in the future relative to the filing date.
• The options and RSUs are not yet exercisable or vested as of July 1, 2026.

Risks

• The value of the stock options and RSUs is subject to market fluctuations and the company's future performance.
• Vesting is contingent on continued service as a director, meaning forfeiture is possible if the director departs before vesting.

Future Outlook

The filing details future vesting and exercise dates for equity awards granted to a director, indicating ongoing compensation arrangements tied to future performance and service.

Industry Context

StockSavvy.ai notes that the granting of stock options and RSUs to directors is a common practice in the biopharmaceutical industry to attract and retain talent and align executive interests with shareholder value.

Related Party Transactions

• Grant of stock options and restricted stock units to Director Joseph Loscalzo.

Stakeholder Impact

• Shareholders: The equity grants align director compensation with company performance and long-term value creation.
• Employees: Indirectly, the retention of experienced directors can contribute to stable company leadership and strategic direction.
• Management: The compensation structure reinforces the company's approach to incentivizing its board members.

Next Steps

• Vesting of stock options and restricted stock units according to the specified schedules.
• Delivery of restricted stock units on July 15th following vesting.
• Potential exercise of stock options after they become exercisable.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, SEC Filing, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership, Insider Trading